The strength of our balance sheet and our strategic collaborations with major biotechnology and pharmaceutical companies provide us with the resources needed to fuel our R&D activities.

More »

Led by a product for multiple sclerosis entering phase 3, we have a pipeline of five products in the clinic.

More »

Abbott completed its acquisition of Facet Biotech on April 21, 2010. Facet Biotech is now a wholly-owned subsidiary of Abbott.

Abbott Completes Acquisition of Facet Biotech

More »